Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations

Leukemia Research

Volumn 38, Issue 12, 2014, Pages 1381-1391

  Santini, Valeria ^a   Prebet, Thomas ^b   Fenaux, Pierre ^c   Gattermann, Norbert ^d   Nilsson, Lars ^e   Pfeilstöcker, Michael ^f   Vyas, Paresh ^g   List, Alan F ^h  

^a UNIVERSITY OF FLORENCE   (Italy)

^b INSTITUT PAOLI CALMETTES   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f HANUSCH HOSPITAL   (Austria)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Azacitidine; Consensus; Hypomethylating agents; MDS; Refractory; Relapse; Salvage therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BIOLOGICAL MARKER; CLADRIBINE; CLOFARABINE; CYTARABINE; ERLOTINIB; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMATOLOGIC AGENT; HYPOMETHYLATING AGENT; LENALIDOMIDE; MITOXANTRONE; PANOBINOSTAT; RIGOSERTIB; SAPACITABINE; SGI 110; TOSEDOSTAT; UNCLASSIFIED DRUG; VORINOSTAT; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; CANCER RECURRENCE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CONSENSUS SEQUENCE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK REDUCTION; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; EUROPE; MORTALITY; MYELODYSPLASTIC SYNDROMES; PRACTICE GUIDELINE; RISK FACTOR;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; EUROPE; HUMANS; MYELODYSPLASTIC SYNDROMES; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SURVIVAL RATE;

EID: 84915785597     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.09.008     Document Type: Review

References (80)

1. Malcovati L., Nimer S.D. Myelodysplastic syndromes: diagnosis and staging. Cancer Control 2008, 15(Suppl.):4-13.
2. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
3. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
4. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Sole F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120:2454-2465.
5. Schanz J., Steidl C., Fonatsch C., Pfeilstocker M., Nosslinger T., Tuechler H., et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011, 29:1963-1970.
6. Mufti G.J., Chen T.L. Changing the treatment paradigm in myelodysplastic syndromes. Cancer Control 2008, 15(Suppl.):14-28.
7. Miller K.B., Kim K., Morrison F.S., Winter J.N., Bennett J.M., Neiman R.S., et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 1992, 65:162-168.
8. Kantarjian H., Beran M., Cortes J., O'Brien S., Giles F., Pierce S., et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006, 106:1099-1109.
9. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Gattermann N., Germing U., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
10. Celgene Europe Ltd. Vidaza summary of product characteristics. Available at: . http://www.medicines.org.uk/EMC/medicine/21508/SPC/Vidaza%2025%20mg%20ml%20powder%20for%20suspension%20for%20injection/.
11. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
12. Silverman L.R., Holland J.F., Weinberg R.S., Alter B.P., Davis R.B., Ellison R.R., et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993, 7(Suppl. 1):21-29.
13. Itzykson R., Thepot S., Quesnel B., Dreyfus F., Beyne-Rauzy O., Turlure P., et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117:403-411.
14. Cluzeau T., Robert G., Karsenti J.M., Luciano F., Legrand F., Mannone L., et al. BCL2L10 is associated with resistance to azacitidine (AZA) in MDS and AML, and is a possible target in resistant patients. Leuk Res 2013, 37(Suppl. 1):S78.
15. Valencia A., Masala E., Rossi A., Martino A., Sanna A., Buchi F., et al. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia 2014, 28:621-628.
16. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-3903.
17. Kadia T.M., Jabbour E., Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol 2011, 38:682-692.
18. Prebet T., Gore S.D., Esterni B., Gardin C., Itzykson R., Thepot S., et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011, 29:3322-3327.
19. Lin K., Reljic T., Kumar A., Lancet J.E., List A.F., Komrokji R.S. Poor outcome of patients with myelodysplastic syndrome (MDS) after azacitidine treatment failure. Blood 2010, 116:2913.
20. Fenaux P., Bowen D., Gattermann N., Hellstrom-Lindberg E., Hofmann W.K., Pfeilstocker M., et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk Res 2010, 34:1410-1416.
21. Santini V., Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Silverman L.R., List A., et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol 2010, 85:130-138.
22. Gore S.D., Hermes-DeSantis E.R. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control 2008, 15(Suppl. 4):40-49.
23. Prebet T., Gore S., Sun Z., Greenberg P., Juckett M., Malick L., et al. Prolonged administration of azacitidine with or without entinostat increases rate of hematolofic normalization for myelodysplastic syndromes and acute myeloid leukemia with myleodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905. Blood 2010, 116. Abstract 601.
24. Krug U.O., Koschmieder A., Gerss J., Serve H., Steffen B., Bug G., et al. Addition of 5-azacitidine to standard induction therapy is feasible in older patients with acute myeloid leukemia: the AML-AZA trial of the SAL study group. Blood 2010, 116:2180.
25. Silverman L.R., Verma A., Odchimar-Reissig R., Feldman E., Navada S.C., Demakos E.P., et al. A phase II trial of epigenetic modulators vorinostat in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS): initial results of study 6898 of the New York cancer consortium. Blood 2013, 122. Abstract 386.
26. Nand S., Godwin J., Smith S., Barton K., Michaelis L., Alkan S., et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma 2008, 49:2141-2147.
27. Sekeres M.A., List A.F., Cuthbertson D., Paquette R., Ganetzky R., Latham D., et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010, 28:2253-2258.
28. Platzbecker U., Ganster C., Neesen J., Kuendgen A., Gotze K., Bug G., et al. Safety and efficacy of a combination of 5-azacitidine followed by lenalidomide in high-risk MDS or AML patients with del(5q) cytogenetic abnormalities - results of the "AZALE" trial. Blood 2011, 118:3799.
29. Sekeres M.A., Tiu R.V., Komrokji R., Lancet J., Advani A.S., Afable M., et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 2012, 120:4945-4951.
30. Jaglal M.V., Duong V.H., Bello C.M., Al Ali N.H., Fernandez H.F., Lancet J.E., et al. Efficacy of cladribine, cytarabine, G-CSF (neupogen), mitoxantrone (CLAG-M regimen) compared to standard 3+7 (anthracycline and cytarabine) in secondary acute myeloid leukemia (sAML) after azanucleosides failure. Blood 2011, 118:256.
31. Bello C., Yu D., Komrokji R.S., Zhu W., Wetzstein G.A., List A.F., et al. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer 2011, 117:1463-1469.
32. Gerds A.T., Gooley T.A., Estey E.H., Appelbaum F.R., Deeg H.J., Scott B.L. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012, 18:1211-1218.
33. Damaj G., Duhamel A., Robin M., Beguin Y., Michallet M., Mohty M., et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the societe francaise de greffe de moelle et de therapie-cellulaire and the groupe-francophone des myelodysplasies. J Clin Oncol 2012, 30:4533-4540.
34. Kantarjian H., O'Brien S., Cortes J., Giles F., Faderl S., Jabbour E., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106:1090-1098.
35. Faderl S., Garcia-Manero G., Jabbour E., Ravandi F., Borthakur G., Estrov Z., et al. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 2012, 118:722-728.
36. Lim S.H., Mcmahan J., Zhang J., Zhang Y. A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine. Leuk Lymphoma 2010, 51:2258-2261.
37. Braun T., Raffoux E., Prebet T., Brechignac S., Stamatoullas A., Dreyfus F., et al. Low-dose clofarabine has significant activity in high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia post-MDS (sAML) after azacitidine (AZA) failure: interim results of the GFM Clo08 dose escalating phase I/II study (NCT0106325). Blood 2011, 118:609.
38. Faderl S., Garcia-Manero G., Estrov Z., Ravandi F., Borthakur G., Cortes J.E., et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 2010, 28:2755-2760.
39. Garcia-Manero G., Luger S.M., Goldberg S., Altman J.K., Arellano M.L., Wetzler M., et al. A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents. Blood (ASH Annu Meet Abstr) 2013, 122. Abstract 2752.
40. Borthakur G., Ahdab S.E., Ravandi F., Faderl S., Ferrajoli A., Newman B., et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008, 49:690-695.
41. Komrokji R.S., Apuri S., Al Ali N.H., Padron E., Pinilla-Ibarz J., Ho V., et al. Evidence for selective benefit of sequential treatment with azanucleosides in patients with myelodysplastic syndromes (MDS). J Clin Oncol 2013, 31(Suppl.). abstr 7113.
42. Sanna A., Gozzini A., Sassolini F., Bosi A., Santini V. Decitabine treatment in higher risk MDS, CMML and AML post-MDS who failed azacitidine. Blood 2011, 118(21 Suppl.). abstr 5052.
43. O'Connell C.L., Tibes R., Walsh K., Rizzieri D., Yee K., Stock W., et al. Outcomes of intermediate or high risk myelodysplastic syndromes (MDS) patients post azacitidine and/or decitabine treatment failures with SGI-110, a novel second generation hypomethylating agent (HMA). Haematologica 2014, 99. Abstract P189.
44. Navada S.C., Odchimar-Reissig R., Reddy E.P., Holland J.F., Wilhelm F., Silverman L.R. Evaluation of rigosertib in patients with a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) relapsed or refractory to hypomethylating agents: a phase I/II study. Blood 2012, 120:3794.
45. Komrokji R.S., Raza A., Lancet J.E., Ren C., Taft D., Maniar M., et al. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol 2013, 162:517-524.
46. Komrokji R.S., List A.F., Yu D., Fulp W.J., Rodriguez Y., Smith P.S., et al. A phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Blood 2011, 118(21 Suppl.):1714.
47. Prebet T., Braun T., Beyne-Rauzy O., Wattel E., Dreyfus F., Stamatoulas A., et al. Final report of GFM-VOR2007 study: a phase I/II study of vorinostat and low dose cytarabine (LDAC) for MDS patients with azacitidine (AZA) failure. ASH Annu Meet Abstr 2012, 120:3825.
48. Flinn I.W., Lang E., Raefsky E., Boccia R., Macias-Perec I.M., Burris H.A., et al. Preliminary results of a phase II trial of panobinostat (LBH589) in refractory myelodysplastic syndromes (MDS) patients. Blood 2010, 116:4015.
49. Prebet T., Charbonnier A., Gelsi-Boyer V., Mozziconacci M.J., Blaise D., Vey N. Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Leuk Lymphoma 2013, 54:1538-1540.
50. Sekeres M.A., O'Keefe C., List A.F., Paulic K., Afable M., Englehaupt R., et al. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Am J Hematol 2011, 86:102-103.
51. Lee J.H., Choi Y., Kim S.D., Kim D.Y., Lee J.H., Lee K.H., et al. Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome. Ann Hematol 2013, 92:889-897.
52. Lee Y.G., Kim I., Yoon S.S., Park S., Cheong J.W., Min Y.H., et al. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. Br J Haematol 2013, 161:339-347.
53. Hollenbach P.W., Nguyen A.N., Brady H., Williams M., Ning Y., Richard N., et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010, 5:e9001.
54. Li L.H., Olin E.J., Buskirk H.H., Reineke L.M. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 1970, 30:2760-2769.
55. Buchi F., Spinelli E., Masala E., Gozzini A., Sanna A., Bosi A., et al. Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. Leuk Res 2012, 36:607-618.
56. Kantarjian H.M., Roboz G.J., Rizzieri D.A., Stock W., O'Connell C.L., Griffiths E.A., et al. Results from the dose escalation phase of a randomized phase 1-2 first-in-human (FIH) study of SGI-110, a novel low volume stable subcutaneous (SQ) second generation hypomethylating agent (HMA) in patients with relapsed/refractory MDS and AML. Blood 2012, 120:414.
57. Clinical Trials.gov. Randomized study of ON 01910. Na in refractory myelodysplastic syndrome patients with excess blasts; . Available at: . http://www.clinicaltrials.gov/ct2/show/NCT01241500.
58. Onconova press release: Onconova announces results from phase 3 ONTIME trial of rigosertib in higher risk myelodysplastic syndromes (MDS). Available at: [accessed March 2014]. http://investor.onconova.com/releasedetail.cfm%3FReleaseID=826761.
59. Boehrer S., Ades L., Braun T., Galluzzi L., Grosjean J., Fabre C., et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008, 111:2170-2180.
60. Lowenberg B., Morgan G., Ossenkoppele G.J., Burnett A.K., Zachee P., Duhrsen U., et al. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol 2010, 28:4333-4338.
61. Itzykson R., Smith A., de Witte T.M., Droste J., Stauder R., Symeonidis A., et al. Prognostic relevance of the kinetics of worsening of cytopenias in lower-risk MDS: a substudy from the European Leukemianet Low Risk MDS (EUMDS) registry. Blood 2012, 120:700.
62. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
63. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
64. Nikoloski G., Langemeijer S.M., Kuiper R.P., Knops R., Massop M., Tonnissen E.R., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010, 42:665-667.
65. Itzykson R., Kosmider O., Cluzeau T., Mansat-De Mas V., Dreyfus F., Beyne-Rauzy O., et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011, 25:1147-1152.
66. Traina F., Jankowska A.M., Visconte V., Sugimoto Y., Szpurka H., Makishima H., et al. Impact of molecular mutations on treatment response to hypomethylating agents in MDS. Blood 2011, 118(21 Suppl.). abstr 461.
67. Raj K., John A., Ho A., Chronis C., Khan S., Samuel J., et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007, 21:1937-1944.
68. Delgado R.G., de Miguel D., Bailen A., Gonzalez J.R., Bargay J., Falantes J.F., et al. Multivariate analysis of the impact of pre-treatment serum ferritin level on response and overall survival in patients with myelodysplastic syndromes treated with azacitidine. Blood 2012, 120:1710.
69. Follo M.Y., Finelli C., Mongiorgi S., Clissa C., Bosi C., Testoni N., et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A 2009, 106:16811-16816.
70. van der Helm L.H., Alhan C., Wijermans P.W., van Marwijk Kooy M., Schaafsma R., Biemond B.J., et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 2011, 155:599-606.
71. Craddock C.F., Goardon N., Quek L., Freeman S., Siddique S., Raghavan M., et al. Quantitation of leukemic stem cell populations predicts clinical outcome in acute myeloid leukaemia. Blood 2011, 118(21 Suppl.):638.
72. Sanna A., Gozzini A., Donnini I., Clissa C., Carrai V., Alterini R., et al. Influence of mild bone marrow fibrosis on response of int-2/high risk MDS patients to 5-azacitidine. Leuk Res 2011, 35(Suppl. 1):S126-S127.
73. Bejar R., Stevenson K., Stojanov P., Zaneveld J.E., Bar-Natan M., Caughey B., et al. Next-generation sequencing of 213 MDS patient samples identifies mutation profiles associated with response to hypomethylating agents and overall survival. Leuk Res 2013, 37:S19-S20.
74. Bally C., Ades L., Renneville A., Mozziconacci M.J., Preudhomme C., DeThe H., et al. Prognostic value of TP53 gene mutations in higher-risk MDS treated with azacitidine (AZA). Leuk Res 2013, 37(Suppl. 1). P-P006.
75. Kulasekararaj A.G., Mohamedali A.M., Smith A.E., Lea N.C., Kizilors A., Abdallah A., et al. Polycomb complex group gene mutations and their prognostic relevance in 5-azacitidine treated myelodysplastic syndrome patients. Blood 2010, 116:125.
76. Voso M.T., Breccia M., Lunghi M., Poloni A., Niscola P., Finelli C., et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol 2013, 90:345-348.
77. Gore S.D., Fenaux P., Santini V., Bennett J.M., Silverman L.R., Seymour J.F., et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013, 98:1067-1072.
78. Choi S.H., Byun H.M., Kwan J.M., Issa J.P., Yang A.S. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol 2007, 138:616-623.
79. Sloand E.M., Wu C.O., Greenberg P., Young N., Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008, 26:2505-2511.
80. Merkel D., Filanovsky K., Gafter-Gvili A., Vidal L., Aviv A., Gatt M.E., et al. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol 2013, 88:130-134.